NCT02718742View on ClinicalTrials.gov

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2016

Primary Completion Date

June 30, 2021

Conditions
Recurrent Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel Albumin-Stabilized Nanoparticle Formulation

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER